Posted in Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use April 21, 2026 Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story